Lerociclib dihydrochloride

• CAT Number: I019886
• CAS Number: 2097938-59-3
• Molecular Formula: C₂₆H₃₆Cl₂N₈O
• Molecular Weight: 547.52
• Purity: ≥95%
• IUPAC Name: 4-[[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one;dihydrochloride
• InChI: InChI=1S/C26H34N8O.2ClH/c1-18(2)32-10-12-33(13-11-32)20-6-7-22(27-16-20)30-25-28-15-19-14-21-24(35)29-17-26(8-4-3-5-9-26)34(21)23(19)31-25;;/h6-7,14-16,18H,3-5,8-13,17H2,1-2H3,(H,29,35)(H,27,28,30,31);2*1H
• InChIKey: IUIVDLVJNPANBY-UHFFFAOYSA-N
• SMILES: CC(C)N1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6.Cl.Cl

Lerociclib dihydrochloride（Cat No.:I019886）is a potent, selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), crucial in regulating the cell cycle. This compound is being explored for its potential in cancer treatment, particularly in hormone receptor-positive (HR+) breast cancer. By inhibiting CDK4/6 activity, Lerociclib induces cell cycle arrest, preventing tumor growth. Its improved safety profile compared to other CDK4/6 inhibitors makes it suitable for combination therapy. Lerociclib dihydrochloride is an important tool in oncology research, offering promise for targeted cancer therapies.

Reference

[1]. Bisi JE, et al. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors. Oncotarget. 2017 Jun 27;8(26):42343-42358.